多发性骨髓瘤的治疗现状

Current treatment at multiple myeloma

多发性骨髓瘤（MM）的治疗取得了突破性进展。20世纪90年代开始，应用造血干细胞移植治疗MM明显提高了疗效，中位总生存期达到5年。近年来，随着多种靶位治疗药物（沙利度胺、硼替佐米、雷利度胺）的临床应用，使得各类型骨髓瘤的预后有了显著改善，据统计中位总生存期又提升了50％。临床资料最新估计，65岁以下患者中位生存期约为10年，老年患者约5。6年。目前正在研制的新药物必将进一步提高患者的疗效。

The breakthrough progress has been made in the treatment of multiple myeloma. Since 1990 s, autologous stem-cell transplantation （ASCT） has resulted in high response rate of MM, and the median overall survival was 5 years. The recent introduction of the novel agents including thalidomide, bortezomib, and lenalidomide further increase the response rate of MM. It is reported that the median overall survival was increased by 50 %. The latest estimates of the median overall survival was about 10 years in under 65 years old patients, and 5-6 years in the elderly patients. The novel agents under investigation will further prolong the overall survival rate and progression free survival in the near future.